X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18649) 18649
Conference Proceeding (124) 124
Dissertation (83) 83
Book Chapter (63) 63
Newspaper Article (60) 60
Publication (25) 25
Government Document (8) 8
Magazine Article (6) 6
Book / eBook (5) 5
Book Review (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
carbazole (5039) 5039
humans (4252) 4252
carbazoles - pharmacology (3965) 3965
animals (3936) 3936
carbazoles (3655) 3655
male (2838) 2838
carbazoles - therapeutic use (2104) 2104
female (1987) 1987
derivatives (1910) 1910
chemistry, multidisciplinary (1885) 1885
rats (1642) 1642
chemistry, organic (1604) 1604
carbazoles - chemistry (1554) 1554
carbazol (1476) 1476
materials science, multidisciplinary (1455) 1455
propanolamines - therapeutic use (1445) 1445
pharmacology & pharmacy (1393) 1393
carvedilol (1387) 1387
fluorescence (1320) 1320
polymers (1253) 1253
carbazole derivatives (1177) 1177
polymer science (1163) 1163
mice (1121) 1121
adrenergic beta-antagonists - therapeutic use (1110) 1110
middle aged (1107) 1107
enzyme inhibitors - pharmacology (1086) 1086
biochemistry & molecular biology (1044) 1044
analysis (1035) 1035
devices (940) 940
indoles - pharmacology (938) 938
chemistry, physical (913) 913
light-emitting-diodes (909) 909
carbazoles - administration & dosage (887) 887
dose-response relationship, drug (865) 865
cardiac & cardiovascular systems (814) 814
propanolamines - pharmacology (812) 812
molecular structure (811) 811
adult (807) 807
physics, applied (768) 768
heart failure - drug therapy (766) 766
electroluminescence (765) 765
aged (763) 763
chemistry, medicinal (722) 722
chemistry (719) 719
cells, cultured (695) 695
synthesis (675) 675
emission (672) 672
carbazoles - chemical synthesis (639) 639
indoles (637) 637
treatment outcome (631) 631
chemistry, applied (613) 613
neurosciences (607) 607
protein kinase c - antagonists & inhibitors (601) 601
phosphorylation (600) 600
activation (589) 589
alkaloids (585) 585
conjugated polymers (585) 585
time factors (579) 579
design (573) 573
engineering, chemical (571) 571
efficiency (568) 568
catalysis (562) 562
copolymers (555) 555
carbazoles - metabolism (532) 532
expression (527) 527
propanolamines - administration & dosage (525) 525
adrenergic beta-antagonists - pharmacology (522) 522
rats, sprague-dawley (522) 522
photoluminescence (520) 520
polymerization (509) 509
indole alkaloids (508) 508
polymer (500) 500
polyvinyl carbazole (497) 497
research (491) 491
heart failure (486) 486
ligands (479) 479
cell line, tumor (474) 474
solar cells (463) 463
cell biology (462) 462
light-emitting diodes (459) 459
organic light emitting diodes (453) 453
poly (449) 449
kinetics (444) 444
physics, condensed matter (442) 442
apoptosis (439) 439
carbazole alkaloids (439) 439
in vitro techniques (438) 438
carbazoles - adverse effects (431) 431
photovoltaic cells (431) 431
organic chemistry (427) 427
pyrroles - pharmacology (421) 421
electrochemistry (419) 419
diodes (415) 415
oncology (415) 415
luminescence (414) 414
structure-activity relationship (414) 414
signal transduction (406) 406
dyes (402) 402
alkaloids - pharmacology (400) 400
chemical properties (399) 399
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18385) 18385
Japanese (370) 370
Chinese (225) 225
German (154) 154
Russian (135) 135
French (102) 102
Korean (63) 63
Portuguese (24) 24
Italian (21) 21
Spanish (21) 21
Polish (16) 16
Czech (9) 9
Turkish (9) 9
Hungarian (7) 7
Ukrainian (7) 7
Danish (4) 4
Dutch (2) 2
Norwegian (2) 2
Swedish (2) 2
Lithuanian (1) 1
Persian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 10/2012, Volume 109, Issue 42, pp. 17010 - 17015
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2012, Volume 337, Issue 6098, pp. 1094 - 1097
Impairment of the circadian clock has been associated with numerous disorders, including metabolic disease. Although small molecules that modulate clock... 
Molecules | Carbazoles | Hepatocytes | HEK293 cells | Chronobiology | Genes | REPORTS | Cell lines | Luminescence | Fibroblasts | Resins | HOMEOSTASIS | CHEMICAL BIOLOGY | METABOLISM | RHYTHMS | PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | PERIOD | DEGRADATION | MAMMALIAN CIRCADIAN CLOCK | OSCILLATIONS | REVEALS | Glucose-6-Phosphatase - genetics | Carbazoles - chemistry | Gluconeogenesis - drug effects | Humans | Molecular Sequence Data | Hepatocytes - metabolism | Phosphoenolpyruvate Carboxykinase (GTP) - genetics | Proteolysis - drug effects | Sulfonamides - isolation & purification | Liver - drug effects | HEK293 Cells | Cryptochromes - agonists | Hepatocytes - drug effects | Cryptochromes - metabolism | Carbazoles - isolation & purification | Amino Acid Sequence | Circadian Clocks - drug effects | Sulfonamides - chemistry | Liver - metabolism | Sulfonamides - pharmacology | Animals | Gluconeogenesis - genetics | Small Molecule Libraries | Protein Stability - drug effects | Cell Line, Tumor | Liver - cytology | Mice | Carbazoles - pharmacology | 3T3 Cells | Circadian rhythms | Ubiquitin | Molecular dynamics | Physiological aspects | Research | Proteins | Biochemistry | Circadian rhythm | Molecular biology | Biotechnology | Biomedical materials | Medical services | Disorders | Derivatives | Chemical compounds | Culture | Biological clocks
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2015, Volume 79, Issue 3, pp. 465 - 476
Journal Article